David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.
Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.
Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.
Boston Scientific's Lotus replacement heart valve shows low leakage rates and no instances of moderate or severe leakage, a problem that plagued the earlier generation of transcatheter aortic valve implants.
The plaintiff's lawyer in the 1st product liability trial over DePuy's Pinnacle hip replacement grills another Johnson & Johnson executive, worldwide clinical research vice president Pamela Plouhar, the at DePuy, over the metal-on-metal implants.
Vector is Children's Hospital Boston's blog about research and innovation in pediatric and adult medicine. We report and comment on medical innovations and advances – from bench to bedside – touching on scientific, business and policy issues. Our ranks include science writers, physicians, lab researchers, market analysts and others inside and outside the hospital.
Technology titan Apple provides its new mobile HealthKit data-aggregation app to researchers at Standford and Duke Universities.
MASSDEVICE ON CALL — Apple (NSDQ:AAPL) is driving home its growing partnership with the healthcare industry by lending its new HealthKit iPhone application to researchers at Stanford and Duke Universities.
Is renal denervation for hypertension dead or alive? Experts agree that more studies are needed.
The efficacy of renal denervation is in doubt and should be confirmed or ruled out in treating resistant hypertension, according to an expert panel in a debate over the once high-flying technology at the Transcatheter Cardiovascular Therapeutics conference in Washington.